Promega™ RNasin™ Ribonuclease Inhibitor: Natural
Ideal for any application where eukaryotic RNase contamination is a potential problem
$270.74 - $666.42
- Inhibits a broad spectrum of RNases, including RNase A, RNase B, RNase C and human placental RNase
- Does not inhibit RNase T1, S1 nuclease, RNase from Aspergillus, RNase H, or RNase ONE™ Ribonuclease
- Compatible with the use of other enzymes, including SP6, T7 or T3 RNA Polymerase, ImProm-II™, AMV or M-MLV Reverse Transcriptase, and Taq DNA Polymerase
1 1U.S. Patents 4,966,964, 5,019,556, and 5,266,687; Australian Patents 616881 and 641261, are exclusively licensed to Promega Corporation.
2 U.S. Patent 5,552,302, Australian Patent 646803.
|Amount of RNasin™ RNase inhibitor required to inhibit the activity of 5ng of RNase A by 50%, activity is measured by the inhibition of hydrolysis of Cytidine 2,3'-cyclic Monophosphate by RNase A|
|RT-PCR, protection of mRNA in cDNA synthesis reactions, in-vitro transcription/translation, Increase yield and activity of polysomes, improvement of in-vitro virus replication, improvement of RNA translation in homologous systems, performing RNase-free Antibody staining, enhancement of RNA yields from Riboprobe™ system RNA synthesis reactions|